# Confluence Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/confluence-life-sciences

- Industry: Pharmaceuticals
- Headquarters: St. Louis, US
- Website: www.confluencelifesciences.com
- Total disclosed funding: $4.2M
- Latest round: Series A (Oct 24, 2013)
- Investors on record: 5

## About

Confluence Life Sciences, Inc. innovates in the life sciences sector, focusing on developing advanced solutions that address complex challenges in drug discovery and development.Established in 2010, Confluence Life Sciences, Inc. is headquartered in St. Louis, US. The company specializes in innovative solutions within the life sciences field. In August 2017, it was acquired in a Trade Sale for USD 10 million by Aclaris Therapeutics, Inc., indicating a strategic pivot towards a more consolidated operational structure. The company has successfully completed 6 deals since its inception.Confluence Life Sciences, Inc. specializes in developing innovative technology solutions for the life sciences industry. Their core offerings include advanced software platforms and tools that optimize operational efficiency, enhance customer engagement, and facilitate data-driven decision-making. These solutions are designed to meet the specific needs of sectors like healthcare, finance, and manufacturing, effectively addressing challenges such as workflow inefficiencies and data silos. The company’s products have gained traction in markets across North America, Europe, and Asia-Pacific, catering to a diverse clientele that ranges from small enterprises to large corporations.The revenue model of Confluence Life Sciences, Inc. includes a combination of subscription services and direct sales of its flagship products. Clients typically enter annual subscription agreements, which provide access to the company's software tools, including ongoing updates and support. This model features a tiered pricing structure, allowing clients to select plans that fit their needs and budgets. Additionally, the company partners with distributors and retailers to enhance market access, while direct-to-consumer segments contribute further through tailored service offerings, all of which support the company's financial stability and growth trajectory.Confluence Life Sciences plans to leverage its recent funding to enhance its product offerings and expand its market reach. The company is designing new products aimed at improving operational processes in drug development, with anticipated releases in the coming year. Additionally, there are initiatives to penetrate new geographic markets, focusing on regions like Europe and Asia by the end of 2024. The recent acquisition by Aclaris Therapeutics, Inc. will provide the necessary resources to support these growth initiatives and solidify the company’s position within the industry.

## Funding rounds

- Series A, Oct 24, 2013, $0.5M — Mercury, Epidarex Capital
- Series A, Sep 17, 2012, $3.7M — Mercury, Epidarex Capital, BioGenerator, Missouri Technology Corporation, Helix Fund

## Investors

- Mercury (https://capitalatlas.ai/funds/mercury) — Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series A
- Missouri Technology Corporation — Series A
- Helix Fund — Series A